Clinical Trial Update: TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing tofacitinib plus hydroxychloroquine versus hydroxychloroquine alone in COVID-19–related interstitial pneumonitis is reported as unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Pneumonitis

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Università Politecnica delle Marche | Conditions: Pneumonitis, Interstitial, COVID-19 | Phase 2 | Status: UNKNOWN